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Abstract: Introduction: Corticosteroids are routinely used in management of chronic obstructive pulmonary disease
(COPD) exacerbation.The main purpose of present study was to compare the efficacy of methyl prednisolone
(MP) and dexamethasone (DXM) forthis purpose. Methods: Adult COPD patients entered the present clinical
trial.All patients received standard treatment on admission andwere then divided into 2 groups of intravenous
MP and DXM. Patients were asked to rate their shortness of breath; sputum volume and viscosity; dyspnea;
cough; and general wellbeing on a 0-5 scale. Baseline parameters such as O2 saturation, arterial blood gas pa-
rameters, and white blood cell (WBC) count were compared on admission and day 7 and 14 of therapy using
SPSS 22. Results: 68 patients were randomly allocated to 2 groups of 34(82.4% male). The baseline character-
istics of the two groups were similar (p < 0.05). Comparison of treatment outcomes for the 7th day showed a
significant difference between the 2 groups only regarding cough (p = 0.047), HCO3 (p < 0.001), and O2 satura-
tion (p = 0.042). Onday 14 the 2 groups were different only regarding cough (p = 0.048) and sputum viscosity (p
= 0.011). There was a significant difference between the two groups regarding trend of changes in dyspnea (p =
0.02 ; DXM À MP) and cough (p = 0.035; MP À DXM). There were no significant differences between the two
medications regarding side effects on 7th and 14th day after treatment. Conclusion:It seems that MP and DXM
have similar efficacy and side effects in treatment of COPD exacerbation and selecting drug of choice would
better be based on the most prominent symptoms of patients on admission.
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1. Introduction
Chronic obstructive pulmonary disease (COPD) is the most
prominent cause of morbidity and mortality in developed
countriesand has raised to become the third cause of mortal-
ity worldwide (1-4). In accordance with international guide-
lines (GOLD), the diagnosis of COPD should be confirmed
with a spirometry result showing a post-bronchodilator value
of FEV1/ FVC ratio <0.7 (5). The key interventions on COPD
exacerbationis to control airway inflammation, relieve air-
flowobstruction and improve ventilation (6). Corticosteroids
are a large group of drugs used in COPD exacerbation and
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are chosen based on clinical presentations of the patient.
It has been shown that using systemic corticosteroids for
treating exacerbation of COPD leads to reduced failed treat-
ments and improves lung function in the first 72 hours and
shortens hospital stay in non- critically ill patients (7-10).
Different types of corticosteroidswith different characteris-
tics, such as methyl prednisolone (MP) and dexamethasone
(DXM), have been used in this regard(11, 12). Based on the
above-mentioned points, the main purpose of present study
was to compare the efficacyof MP and DXM in treatment of
COPD exacerbation.
2. Methods
2.1. Study design and settings
This is a prospective, randomized, single-blind trial con-
ducted between 2013 and 2014 in Al-Zahra Hospital, Isfa-
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han, Iran. The institutional review board of Isfahan Univer-
sity of Medical Sciences approved the study protocol. All pa-
tients gave their written informed consent and the protocol
was approved by the hospital’s Ethics Committee. The re-
searchers adhered to the principles of Helsinki Declaration
over the course of the study. The protocol of the present study
was registered on Iranian registry of clinical trials under IRCT
number:
2.2. Participants
All studied patients met the criteria outlined in the guidelines
for diagnosis and management of COPD, established by the
GOLD standard (13). Adult COPD patients with acute res-
piratory distress, increasedcough frequency and severity, in-
creased sputum volume, and/or increased wheezing for 24
hours or more were eligible for entry to the study. Patients
with history of asthma or atopy, onset of respiratory distress
before the age of 35 years, absence of spirometric data, or
having received oral or intravenous steroids in the month
prior to presentation were excluded. The 68 cases were ran-
domly allocated to two equal groups of 34, using simple ran-
domization method. Patients and data analyser were blinded
to type of treatment.
2.3. Intervention
On admission to ED, oxygen therapy was performed until O2
saturation raised to above 88-90%. In addition, all individ-
uals in both groups received a combination of a macrolide
(azithromycin) and a third generation cephalosporin (cef-
triaxone); nebulized β2-agonist (salbutamol), anticholiner-
gic agent (ipratropium bromide), and inhaled corticosteroid
(budesonide). They were then divided into 2 groups of MP
and DXM for receiving intravenous (IV) corticosteroid. The
MP group received 2 mg/kg/day MP intravenously for 3 days.
Then the dose was reduced to 40 mg for 3 days and switched
to 30 mg/day of oral prednisone, which was tapered every
3 days with 5 mg decrease in dosage. Then inhaled budes-
onide, 400 micrograms, twice a day was prescribed. Pred-
nisone was tapered for 2 weeks, and then ceased. Inhaled
corticosteroid had to be used for at least 3 months con-
tinuously. The second group (DXM group) received 0.375
mg/kg DXM per day, and then its dosage was gradually ta-
pered. After 7 to 14 days, the drug was replaced by 30 mg/day
methyl prednisone, and continued by the same protocol as
MP group.
2.4. Assessments
Patients were assessed within an hour of admission and then
every day for two weeks to evaluate the therapeutic effect of
treatment and the side effects. Questions were asked about
shortness of breath; sputum volume and viscosity; dyspnea;
cough; and general wellbeing on admission and on every day
of therapy. Patients were asked to score each symptom from 0
(much better than usual) to 5 (much worse than usual). Base-
line parameters such as O2 saturation, arterial blood gaspa-
rameters, andwhite blood cell (WBC) count were evaluated
on admission and on day 7 and 14 of therapy. Potential cor-
ticosteroid side effects such as mood changes, heartburn,
overt gastrointestinal bleeding, and blood sugar disturbance
were recorded in every visit.
2.5. Statistical analysis
Sample size was calculated to be 33 in each group based on
Zα = 1.96, Zβ = 0.84, s = 12.4, and d = 8.6. All data from
the patients were analysed using independent sample T- test
or Mann-Whitney U test for quantitative variables and Chi-
square test for qualitative variables. Chi- square for trend
analysis was used to compare trend of changes in sputum
volume and viscosity as well as dyspnea and cough between
the two groups.A value of p < 0.05 was consideredto indicate
statistical significance. All data are reported as mean ± stan-
dard deviation (SD). Analyses were done using SPSS software
version 22.0 (SPSS Inc, Chicago, IL).
3. Results
68 COPD patients were randomly allocated to 2 equal groups
of DXM (82.3% male) and MP (82.4% male). The mean age of
DXM and MP groups were 74.67± 1.79 and 73.35± 2.25 years,
respectively (p = 0.648). Baseline characteristics of the two
groups were compared in table 1. There were no significant
differences between the two medications regarding side ef-
fects on 7th and 14th day after treatment (table 2). Outcome
of studied groups on 7th and 14th days after treatment were
presented in table 3 and figure 1. 7-day treatment outcome
Comparison of treatment outcomes for the 7th day showed
a significant difference between the 2 groups only regarding
cough (p = 0.047; remission: MP: 23 (67.7%) vs. DXM: 16
(48.5%) ), HCO3 (MP: 22.58 ± 3.62 vs DXM: 25.66 ± 2.82; p
< 0.001), and O2 saturation (MP: 87.71 ± 3.15 vs DXM: 89.24
± 2.88; p = 0.042). 14-day treatment outcome Comparison
of treatment outcomes for the 14th day showed a significant
difference between the 2 groups only regarding cough (p =
0.048; remission: MP: 27 (79.4%) vs. DXM: 25 (75.7%) ) and
sputum viscosity (p = 0.011; remission: MP: 34 (100%) vs.
DXM: 24 (72.7%) ). Trend of changes There were not any sig-
nificant differences between the 2 groups regarding trend of
changes in sputum volume (p = 0.05), sputum viscosity (p =
0.24), O2 saturation (p = 0.87), PaCO2 (p = 0.83), HCO3 (p =
0.12), serum pH (p = 0.42), WBC count (p = 0.24), on 7thand
14th day after treatment. There was a significant difference
between the two groups regarding trend of changes in dysp-
nea (p = 0.02; DXM ÀMP) and cough (p = 0.035; MP À DXM).
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Table 1: Baseline characteristics of the patients in the two groups
Variables Dexamethasone Methylprednisolone P
Duration of disease
Years 8.02 ± 5.25 8.64 ± 4.61 0.608
Shortness of breath
None 4 (11.8) 0(0)
0.792
Mild 3 (8.8) 6 (17.6)
Moderate 7 (20.6) 8 (23.5)
Severe 20 (58.8) 20 (58.8)
Cough
None 4 (11.8) 0(0)
0.556
Mild 2 (5.9) 3 (8.8)
Moderate 9 (26.5) 11 (32.4)
Severe 19 (55.9) 20 (58.8)
Sputum volume
None 8 (23.5) 0(0)
0.081
Mild 5 (14.7) 8 (23.5)
Moderate 5 (14.7) 5 (14.7)
Severe 16 (47.1) 21 (61.8)
High sputum viscosity
Yes 18 (52.9) 21 (61.8)
0.624
No 16 (47.1) 13 (38.2)
O2 saturation
On arrival 79.26 ± 6.61 78.65 ± 8.24 0.734
PaCO2
On arrival 64.85 ± 10.00 64.85 ± 12.52 1.000
HCO3
On arrival 26.55 ± 5.37 27.76 ± 5.52 0.365
PH
On arrival 7.32 ± 0.04 7.30 ± 0.05 0.218
White blood cell count/mm3
Before treatment 8.49±3.6 7.35±3.08 0.164
4. Discussion
The findings of this study demonstrated that although both
treatments are effective and similar in most treatment char-
acteristics, MP is better for reducing cough, and sputum vis-
cosity, while DXM showed a significantly better trend regard-
ing dyspnea treatment and increased O2 saturation, more
significantly on the 7th day. Although a significant differ-
ence was detected between the 2 groups regarding HCO3, it
is not clinically significant. Despite accepted effects of corti-
costeroids on airflow obstruction relief and being usedsince
1950, drug of choice, optimal dose, and duration of treat-
ment remain unclear(14). Several studieshave demonstrated
that corticosteroids can significantly improve patients symp-
toms and lung function (15-18). Li et al. had compared MP
with DXM, with the same dosage as this study, in acute exac-
erbation of COPD and believed that DXM was less effective
than MP, as cough and sputum in MP group were relieved
more quickly than DXM group (6). The present study also
showed a significant difference in cough relief in MP group.
Yet, although the change in trend was similar in both groups,
MP group showed significantly better sputum viscosity re-
mission only on the 14th day. Zhao et al. also compared
these drugs in severe pediatric asthmatic bronchitis and con-
cluded that MP is superior to DXM for this purpose. However,
in contrast to the present findings, they demonstrated that
MP retrieves hypoxia quickly (19). Li et al. also demonstrated
that, there was no striking difference in blood gas improve-
ment between the two groups, although the effect of MP
seemed slightly superior to that of DXM (6). This is in con-
trast to our results showing higher O2 saturation on the 7th
day in DXM group. Andre et al. compared MP and DXM in
premature infants who were at risk of chronic lung diseases
and concluded that MP is as efficient as DXM with fewer side
effects (20). In this study, we found that they were both effec-
tive, but they were not significantly different regarding side
effects. DXM has well- known pharmacologic properties, in-
cluding duration of action of up to 72 hours, a relatively long
half-life, and excellent bioavailability (21). As a result, it has
been proffered as an alternative to prednisone thatmay allow
shorter treatment regimens and improved compliance. Joel
Kravitz et al. indicated that 2 days of oral DXM is at least as
effective as 5 days of prednisone in the treatment of mild to
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Table 2: Comparison of drug side effects between the two groups







7 3 (9.1) 2 (5.9) 0.67
14 3 (9.1) 5 (14.7) 0.71
Mood change
7 0 (0) 2 (5.9) 0.49
14 0 (0) 3 (8.8) 0.24
Heart burn
7 6 (18.2) 4 (11.8) 0.51
14 9 (27.3) 6 (17.6) 0.39
Blood sugar
disturbance
7 6 (18.2) 4 (11.8) 0.51
14 9 (27.3) 6 (17.6) 0.39
moderate asthma exacerbation. Relapse and treatment fail-
urerates were equivalent in both groups (22). It seems that
selection of corticosteroids in COPD exacerbation should be
performed based on the most prominent symptom of pa-
tients. In cough prominent cases, MP seems to have better
effects and in sputum prominent cases, DXM is superior.
5. Limitations
Single blinding (drug administrator was not binded), lack of
long term follow-up regarding times of readmission with ex-
acerbation, and qualitative measurement based on patient-
declaration are among the most important limitations of
present study.
6. Conclusion
Our study showed that MP and DXM have similar efficacy
and side effects in treatment of patients with COPD exacer-
bation and selectingdrug of choicewouldbetter be basedon
the most prominent symptoms of patients.
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